Bright Minds Biosciences Faces Investor Concerns Amid Stock Drop Bright Minds Biosciences' stock (NASDAQ:DRUG) recently saw a sharp decline in trading volume, dropping 0.8% to $35.78. Analysts remain optimistic with strong buy ratings, but investor interest appears to waver. Institutional investors have made significant moves, with ownership now at 40.52%, reflecting mixed confidence in the company's outlook.12